#VisualAbstract: Pembrolizumab plus gemcitabine and cisplatin improves survival in advanced biliary tract cancer
1. Median overall survival was greater in the pembrolizumab group compared to the control group (12.7 months vs. 10.9 months). 2. ...
Tag: biliary tract cancer
Pembrolizumab plus gemcitabine and cisplatin improves survival in advanced biliary tract cancer
1. Median overall survival was greater in the pembrolizumab group compared to the control group (12.7 months vs. 10.9 months). ...
Adjuvant S-1 increases short-term survival in patients with resected biliary tract cancer
1. Patients who received adjuvant S-1 had prolonged overall survival and relapse-free survival compared to those who were managed with ...